Citius Oncology (CTOR) Stock Price, News & Analysis

Company Overview

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Key Stats

• Today's Range: $1.16 to $1.27
• 50-Day Range: $0.85 to $1.62
• 52-Week Range: $0.85 to $49.00
• Volume: 84,505 shs
• Average Volume: 171,084 shs
• Market Capitalization: $87.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Buy

CTOR Stock Analysis - Frequently Asked Questions

How have CTOR shares performed this year?

Citius Oncology's stock was trading at $1.15 at the beginning of 2025. Since then, CTOR stock has increased by 6.1% and is now trading at $1.22.
View the best growth stocks for 2025 here.

How do I buy shares of Citius Oncology?

Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Citius Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC).

Company Calendar

• Today: 1/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CTOR
• Previous Symbol: NASDAQ:CTOR
• CUSIP: N/A
• CIK: 1851484
• Web: www.citiusonc.com
• Phone: 347-627-0058
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $3.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +145.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,150,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -100.17%
• Return on Assets: -15.19%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 0.34
• Quick Ratio: 0.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.22) per share
• Price / Book: -5.55

Miscellaneous

• Outstanding Shares: 71,550,000
• Free Float: 55,167,000
• Market Cap: $87.29 million
• Optionable: N/A
• Beta: -0.64